Tuech Jean-Jacques, Pessaux Patrick, Regenet Nicolas, Daver Alain, Lorimier Gerard, Bergamaschi Roberto, Arnaud Jean-Pierre
Department of Digestive Surgery, Angers University Hospital, 4 rue Larrey, Angers, France.
J Surg Oncol. 2004 Oct 1;88(1):27-31. doi: 10.1002/jso.20116.
It has been suggested that bile CEA levels could be a sensitive index for the detection of occult liver metastases (LM) in colorectal cancer (CRC) patients. The aim of this study was to determine the potential value of biliary CEA assay in the early detection of occult LM from CRC.
From 1995 to 1999 biliary and blood CEA levels were determined in three groups of patients undergoing surgery; Group 1 (n = 35) patients with LM from CRC; Group 2 (n = 154) patients with CRC without LM; Group 3 (n = 23) was the control group.
Biliary and serum CEA levels were significantly lower in group 3 than in group 2 (P = 0.008 and P = 0.002) and in group 2 than in group 1 (P = 0.001 and P = 0.005). With a follow-up of 36 months (group 2), 22 patients (14%) developed LM. For 59 patients, the bile CEA level during laparotomy was less than 5 ng/ml and for 95 patients this level was more than 5 ng/ml, 4 and 18 patients respectively developed metachronous LM; we found a difference (P = 0.03) between these two subgroups. When this analysis was performed with regard to the stage of the tumor, we found no difference for the node negative cancer (n = 79) subgroup (P = 0.6), but we found a significant difference for the node positive cancer (n = 75) subgroup (P = 0.01).
Our data suggest that biliary CEA concentrations at the time of resection of the primary tumor cannot be used to identify patients with occult LM in the node-negative CCR subgroup. However, patients with node-positive CCR and bile CEA level under 5 ng/ml developed LM in only 3% of cases; it might be therefore, possible to use that as a discriminant in situations where the risk of LM is small.
有人提出,胆汁癌胚抗原(CEA)水平可能是检测结直肠癌(CRC)患者隐匿性肝转移(LM)的敏感指标。本研究的目的是确定胆汁CEA检测在早期发现CRC隐匿性LM中的潜在价值。
1995年至1999年,对三组接受手术的患者测定胆汁和血液CEA水平;第1组(n = 35)为患有CRC肝转移的患者;第2组(n = 154)为无肝转移的CRC患者;第3组(n = 23)为对照组。
第3组的胆汁和血清CEA水平显著低于第2组(P = 0.008和P = 0.002),第2组低于第1组(P = 0.001和P = 0.005)。在36个月的随访期内(第2组),22例患者(14%)发生了肝转移。59例患者在剖腹手术时胆汁CEA水平低于5 ng/ml,95例患者该水平高于5 ng/ml,分别有4例和18例患者发生异时性肝转移;我们发现这两个亚组之间存在差异(P = 0.03)。当对肿瘤分期进行该分析时,我们发现淋巴结阴性癌(n = 79)亚组无差异(P = 0.6),但淋巴结阳性癌(n = 75)亚组存在显著差异(P = 0.01)。
我们的数据表明,在淋巴结阴性的CRC亚组中,原发肿瘤切除时的胆汁CEA浓度不能用于识别隐匿性肝转移患者。然而,淋巴结阳性的CRC且胆汁CEA水平低于5 ng/ml的患者仅3%发生肝转移;因此,在肝转移风险较小的情况下,有可能将其用作判别指标。